<DOC>
	<DOCNO>NCT02617485</DOCNO>
	<brief_summary>The aim study demonstrate high level biosimilarity MabionCD20 ( MABION SA ) reference product : MabThera ( rituximab Hoffman-La Roche ) patient CD20-positive diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>MabionCD20® Compared MabThera® Lymphoma Patients</brief_title>
	<detailed_description>Patients meet criterion participation study receive 8 intravenous infusion MabionCD20® MabThera® 21 day interval combination standard dosage regimen CHOP . The duration study 12 month . The treatment observation period last 26 week start Day 1 , Week 26 - one month last IMP infusion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients histological confirm CD20 ( cluster differentiation 20 ) positive diffuse large B cell lymphoma ( DLBCL ) 2 . Patients diagnose accord WHO classification ; 3 . Performance status ≤ 2 ECOG ( Eastern Cooperative Oncology Group ) / WHO ( world Health Organization ) scale , performance status 3 accept impairment cause DLBCL complication improvement expect therapy initiate ; 1 . Life expectance le 6 month ; 2 . Any chemotherapy , radiotherapy , immunotherapy , biologic , investigational hormonal therapy treatment lymphoma within 28 day prior treatment ; 3 . Rituximab , antiCD20 mAb ( Monoclonal Antibodies ) drug treatment , treatment cell deplete therapy e.g. , antiCD4 ( cluster differentiation 4 ) antiCD5 ( cluster differentiation 5 ) , antiCD3 ( cluster differentiation 3 ) , antiCD19 ( cluster differentiation 19 ) , anti CD11 ( cluster differentiation 11 ) , antiCD22 ( cluster differentiation 11 ) , BLys/BAFF ( B Lymphocyte Stimulator/Bcell activate factor ) within 1,5 year screen ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>